Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy.
about
Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD.A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients.Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
P2860
Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Treatment of hepatitis C in pa ...... rect-acting antiviral therapy.
@en
type
label
Treatment of hepatitis C in pa ...... rect-acting antiviral therapy.
@en
prefLabel
Treatment of hepatitis C in pa ...... rect-acting antiviral therapy.
@en
P2860
P1433
P1476
Treatment of hepatitis C in pa ...... rect-acting antiviral therapy.
@en
P2093
Matthew T Kitson
Stuart K Roberts
P2860
P2888
P304
P356
10.1007/S40265-015-0401-2
P577
2015-05-01T00:00:00Z
P5875
P6179
1040267329